Opinion · United States Court of Appeals for the Federal Circuit
IN RE CYCLOBENZAPRINE HYDROCHLORIDE, 424 Fed.Appx. 952 (Fed. Cir. 2011)
In re CYCLOBENZAPRINE HYDROCHLORIDE EXTENDED-RELEASE CAPSULE PATENTLITIGATION. Eurand, Inc., Cephalon, Inc., & Anesta AG,Plaintiffs-Appellees, v. Mylan Pharms. Inc. & Mylan Inc.,Defendants-Appellants., 424 F. App'x 952 (Fed. Cir. 2011)
- Type
- Opinion
- Court
- United States Court of Appeals for the Federal Circuit
- Jurisdiction
- Federal
- Date
- 2011-05-25
- Topic
- general
IN RE CYCLOBENZAPRINE HYDROCHLORIDE, 424 Fed.Appx. 952 (Fed. Cir. 2011) In re CYCLOBENZAPRINE HYDROCHLORIDE EXTENDED-RELEASE CAPSULE PATENTLITIGATION. Eurand, Inc., Cephalon, Inc., and Anesta AG,Plaintiffs-Appellees, v. Mylan Pharmaceuticals Inc. and Mylan Inc.,Defendants-Appellants. No. 2011-1399.United States Court of Appeals, Federal Circuit.
Citator
UpLaw has not yet analyzed IN RE CYCLOBENZAPRINE HYDROCHLORIDE, 424 Fed.Appx. 952 (Fed. Cir. 2011). The absence of a flag is not a finding that it is good law.
James H. Wallace Jr., Kevin P. Anderson, Robert J. Scheffel, Mark A. Pacella, Brian H. Pandya, Matthew J. Dowd, Wiley Rein LLP, Washington, DC, for Defendants-Appellants.Page 953
Upon consideration thereof,
IT IS ORDERED THAT:
(1) Eurand, Inc. et al. are directed to respond no later, than 12:00 p.m. on May 31, 2011.
(2) Mylan's request for an immediate stay is granted to the extent that the injunction is temporarily stayed pending the court's receipt of the response and the court's consideration of the papers submitted.
- [EDITOR'S NOTE: This case is unpublished as indicated by the issuing court.] ↩